Cambridge, UK | 2nd November 2011


Isogenica today announced the appointment of Göran Forsberg to the Board of Directors.

Currently Chief Business Officer (CBO) at Active Biotech in Lund, Sweden, Göran brings extensive industry experience to Isogenica. He holds a Ph.D. in Biochemistry from the Royal Institute of Technology, Stockholm, Sweden and has authored approximately 40 scientific articles primarily within biochemistry, molecular biology, immunology and cancer research. Göran has worked in the pharmaceutical industry for almost 25 years as a scientist, project leader or department head within KabiGen, Pharmacia and the University of Adelaide. Since 2008, he has been responsible for business development at Active Biotech, a company developing new products for the treatment of autoimmune diseases and cancer with three products in pivotal clinical studies.

Dr Kevin Matthews, CEO, Isogenica commented of the appointment:

We are delighted to welcome Göran to the board.  His significant experience within the industry, both at a scientific and commercial level, will be invaluable to Isogenica as we continue to expand our capabilities – working in partnership with our clients to discover highly active lead candidates for drug development – with the ultimate goal of identifying channels to market for these new and potent therapeutic peptides.”


Isogenica has enjoyed significant expansion of its capabilities during 2011.  March saw the establishment of a dedicated business development and customer support team in North America, providing direct support to Isogenica’s existing and prospective customers in the United States and Canada. In July the company announced the opening of a new automation facility at their current UK base, Chesterford Research Park. Following a substantial refit of additionally acquired space, the new facility is now home to the high throughput CIS display platform used in the discovery of biological therapeutics, diagnostics and reagents using Tecan liquid handling robots and screening equipment. This development brings additional capacity to the company for the selection of next generation molecules for biopharmaceutical projects with a capacity of up to two hundred selections per week.